HEPION PHARMACEUTICALS INC (HEPA) Stock Price, Quote, News and Overview
NASDAQ:HEPA - Nasdaq - US4268973025 - Common Stock - Currency: USD
HEPA Quote, Performance and Key Statistics
HEPION PHARMACEUTICALS INC
NASDAQ:HEPA (1/23/2025, 4:16:09 PM)
After market: 0.182 -0.02 (-9%)0.2
+0.07 (+48.15%)
The current stock price of HEPA is 0.2 USD. In the past month the price decreased by -74.48%. In the past year, price decreased by -92.66%.
HEPA Latest News, Press Releases and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
These stocks are moving in today's session
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Let's have a look at the most active stocks in today's session.
The trading volume of these stocks is deviating from the norm in today's session.
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Which stocks are gapping on Thursday?
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
HEPA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 75.38 | 727.75B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.21 | 360.19B | ||
| JNJ | JOHNSON & JOHNSON | 14.68 | 353.05B | ||
| MRK | MERCK & CO. INC. | 16.24 | 244.44B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.01 | 212.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.41 | 199.99B | ||
| PFE | PFIZER INC | 10.25 | 149.84B | ||
| SNY | SANOFI-ADR | 12.41 | 130.32B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.55 | 119.95B | ||
| ZTS | ZOETIS INC | 28.99 | 75.33B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 69.47B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B |
Related screens
About HEPA
Company Profile
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. The company is headquartered in Edison, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-02-07. The firm is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. The company is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. The company has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.
Company Info
HEPION PHARMACEUTICALS INC
399 Thornall St
Edison NEW JERSEY 08837 US
CEO: Robert Foster
Employees: 22
Company Website: https://hepionpharma.com/
Investor Relations: http://hepionpharma.com/investors/
Phone: 17329024000
HEPA FAQ
What is the price of HEPA?
The current price of HEPA is 0.2 USD.
What is the symbol for HEPION PHARMACEUTICALS INC?
The exchange symbol of HEPION PHARMACEUTICALS INC is HEPA and it is listed on the Nasdaq exchange.
On which exchange is HEPA listed?
HEPA is listed on the Nasdaq exchange.
Is HEPA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for HEPA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of HEPA.
Does HEPA pay dividends?
HEPA does not pay a dividend.
What is the Price/Earnings (PE) ratio of HEPA?
HEPA does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.32).
What is the Short Interest ratio of HEPA?
The outstanding short interest for HEPA is 0.35% of its float.
HEPA Technical Analysis
HEPA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HEPA. HEPA has a bad profitability rating. Also its financial health evaluation is rather negative.
HEPA Financial Highlights
Over the last trailing twelve months HEPA reported a non-GAAP Earnings per Share(EPS) of -12.32. The EPS decreased by -4.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -611.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HEPA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to HEPA. The Buy consensus is the average rating of analysts ratings from 7 analysts.